LCNB Corp’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.41M | Buy |
9,248
+42
| +0.5% | +$6.44K | 0.47% | 46 |
|
|
2025
Q4 | $1.27M | Sell |
9,206
-25
| -0.3% | -$3.27K | 0.43% | 52 |
|
|
2025
Q3 | $1.18M | Sell |
9,231
-90
| -1% | -$11K | 0.41% | 56 |
|
|
2025
Q2 | $1.13M | Sell |
9,321
-75
| -0.8% | -$8.45K | 0.4% | 62 |
|
|
2025
Q1 | $1.05M | Sell |
9,396
-178
| -2% | -$18.9K | 0.39% | 66 |
|
|
2024
Q4 | $932K | Hold |
9,574
| – | – | 0.34% | 74 |
|
|
2024
Q3 | $1.1M | Sell |
9,574
-730
| -7% | -$82.8K | 0.39% | 62 |
|
|
2024
Q2 | $1.1M | Sell |
10,304
-505
| -5% | -$50.7K | 0.41% | 56 |
|
|
2024
Q1 | $1.05M | Sell |
10,809
-575
| -5% | -$59K | 0.38% | 64 |
|
|
2023
Q4 | $1.15M | Sell |
11,384
-175
| -2% | -$16.9K | 0.45% | 53 |
|
|
2023
Q3 | $1.18M | Sell |
11,559
-385
| -3% | -$39.1K | 0.52% | 46 |
|
|
2023
Q2 | $1.21M | Buy |
11,944
+373
| +3% | +$37.3K | 0.51% | 49 |
|
|
2023
Q1 | $1.06M | Sell |
11,571
-600
| -5% | -$52.4K | 0.48% | 57 |
|
|
2022
Q4 | $1.1M | Sell |
12,171
-250
| -2% | -$21.1K | 0.51% | 53 |
|
|
2022
Q3 | $944K | Sell |
12,421
-325
| -3% | -$26.9K | 0.51% | 54 |
|
|
2022
Q2 | $1.08M | Sell |
12,746
-494
| -4% | -$43.3K | 0.56% | 50 |
|
|
2022
Q1 | $1.16M | Buy |
13,240
+1,285
| +11% | +$111K | 0.55% | 51 |
|
|
2021
Q4 | $1.05M | Buy |
11,955
+31
| +0.3% | +$2.57K | 0.48% | 59 |
|
|
2021
Q3 | $975K | Sell |
11,924
-149
| -1% | -$13.4K | 0.49% | 57 |
|
|
2021
Q2 | $1.1M | Sell |
12,073
-114
| -0.9% | -$10.2K | 0.55% | 51 |
|
|
2021
Q1 | $1.04M | Hold |
12,187
| – | – | 0.57% | 49 |
|
|
2020
Q4 | $1.15M | Sell |
12,187
-400
| -3% | -$35K | 0.65% | 42 |
|
|
2020
Q3 | $1.09M | Sell |
12,587
-292
| -2% | -$25.3K | 0.72% | 38 |
|
|
2020
Q2 | $1.13M | Buy |
12,879
+354
| +3% | +$30.6K | 0.76% | 31 |
|
|
2020
Q1 | $1.03M | Sell |
12,525
-75
| -0.6% | -$6.69K | 0.81% | 36 |
|
|
2019
Q4 | $1.19M | Sell |
12,600
-425
| -3% | -$38.1K | 0.73% | 37 |
|
|
2019
Q3 | $1.13M | Buy |
13,025
+408
| +3% | +$36.6K | 0.73% | 37 |
|
|
2019
Q2 | $1.15M | Sell |
12,617
-3,859
| -23% | -$327K | 0.81% | 31 |
|
|
2019
Q1 | $1.42M | Sell |
16,476
-324
| -2% | -$26K | 1.03% | 25 |
|
|
2018
Q4 | $1.29M | Hold |
16,800
| – | – | 1.07% | 24 |
|
|
2018
Q3 | $1.3M | Sell |
16,800
-592
| -3% | -$43.8K | 0.92% | 27 |
|
|
2018
Q2 | $1.18M | Buy |
17,392
+2,127
| +14% | +$147K | 1.06% | 23 |
|
|
2018
Q1 | $1.1M | Sell |
15,265
-271
| -2% | -$20.6K | 0.99% | 27 |
|
|
2017
Q4 | $1.17M | Sell |
15,536
-128
| -0.8% | -$9.66K | 1.03% | 26 |
|
|
2017
Q3 | $1.21M | Buy |
15,664
+29
| +0.2% | +$2.19K | 1.13% | 22 |
|
|
2017
Q2 | $1.17M | Hold |
15,635
| – | – | 1.14% | 21 |
|
|
2017
Q1 | $1.04M | Sell |
15,635
-248
| -2% | -$16.5K | 0.99% | 27 |
|
|
2016
Q4 | $1.04M | Buy |
+15,883
| New | +$1.03M | 1.02% | 25 |
|
Other funds holding NVS
LCNB Corp's NVS Position: Q1 2026 in Review
LCNB Corp increased its Novartis (NVS) stake by 0.46% in Q1 2026, buying an estimated $6.44K and bringing the position to 9,248 shares worth $1.41M. The position accounts for 0.47% of the portfolio, ranked #46.
LCNB Corp first reported a position in NVS in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.42M in Q1 2019. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- LCNB Corp held 9,248 shares of Novartis worth $1.41M as of Q1 2026.
- LCNB Corp bought 42 Novartis shares in Q1 2026, an estimated $6.44K.
- Novartis made up 0.47% of LCNB Corp's portfolio in Q1 2026, its #46 holding.
- LCNB Corp first reported a position in Novartis in Q4 2016 and has held it in 38 quarters since.
- LCNB Corp's Novartis position peaked at $1.42M in Q1 2019.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on LCNB Corp's 13F filing for Q1 2026, filed 11 May 2026.